Simcyp
| Company type | Private |
|---|---|
| Industry | Pharmacokinetic modelling & simulation |
| Founded | Sheffield, UK (2001) |
| Headquarters | , United Kingdom  |
| Products | Simcyp Population-based ADME Simulator Simcyp Paediatric Simcyp Rat |
| Website | www.simcyp.com |
Simcyp Limited is a research-based company which provides modelling and simulation software to the pharmaceutical industry for use during drug development. Simcyp is based in Sheffield, UK.
Simcyp’s Simulators allow in silico prediction of drug absorption, distribution, metabolism and excretion (ADME) and potential drug-drug interactions.
Research and development
Simcyp’s R&D activities focus on the development of algorithms along with population and drug databases for modelling and simulation (M&S) of the absorption and disposition of drugs in patients and specific subgroups of patients across different age ranges. The Simcyp models use experimental data generated routinely during pre-clinical drug discovery and development from in vitro enzyme and cellular systems, as well as any relevant physico-chemical attributes of the drug and dosage forms.[1] Some details of the scientific background to Simcyp approaches can be found in recent publications.[2][3][4][5]
Background
Simcyp originally formed as a spin-out company from the University of Sheffield, UK. The company operates the Simcyp Consortium of pharmaceutical and biotechnology companies. The Consortium acts as a steering committee, guiding scientific research and development at Simcyp. There is also close collaboration with regulatory bodies (the U.S. Food and Drug Administration, Swedish Medical Products Agency, NAM, ECVAM) and academic centres of excellence worldwide, within the framework of the Consortium.
Simulator platforms
- Simcyp Population-based ADME Simulator[6]
- Simcyp Paediatric
- Simcyp Rat
- Simcyp Dog
- Simcyp Mouse
References
- ^ Rostami-Hodjegan A, Tucker GT (February 2007). "Simulation and prediction of in vivo drug metabolism in human populations from in vitro data". Nature Reviews Drug Discovery. 6 (2): 140–8. doi:10.1038/nrd2173. PMID 17268485.
- ^ Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A (October 2007). "Prediction of intestinal first-pass drug metabolism". Curr. Drug Metab. 8 (7): 676–84. doi:10.2174/138920007782109733. PMID 17979655.
- ^ Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A (July 2007). "Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition". Eur J Pharm Sci. 31 (3–4): 232–41. doi:10.1016/j.ejps.2007.04.005. PMID 17512176.
- ^ Perrett HP, et al. (2007). "Disparity in holoprotein/apoprotein ratios of different standards used for immunoquantification of hepatic cytochrome P450 enzymes". Drug Metabolism & Disposition. 35 (10): 1733–1736. doi:10.1124/dmd.107.015743. PMID 17600083.
- ^ Yang J, Jamei M, Yeo KR, Rostami-Hodjegan A, Tucker GT (March 2007). "Misuse of the well-stirred model of hepatic drug clearance". Drug Metab. Dispos. 35 (3): 501–2. doi:10.1124/dmd.106.013359. PMID 17325025.
- ^ Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A (February 2009). "The Simcyp((R)) Population-based ADME Simulator". Expert Opin Drug Metab Toxicol. 5 (2): 211–223. doi:10.1517/17425250802691074. PMID 19199378.